Scarica l'app Stockscreener
8.17
2.51%
0.20
Pre-mercato:
8.02
-0.15
-1.84%
Precedente Chiudi:
$7.97
Aprire:
$7.62
Volume 24 ore:
3.62M
Relative Volume:
3.53
Capitalizzazione di mercato:
$580.81M
Reddito:
-
Utile/perdita netta:
$-119.87M
Rapporto P/E:
-4.5138
EPS:
-1.81
Flusso di cassa netto:
$-109.90M
1 W Prestazione:
+28.66%
1M Prestazione:
+44.47%
6M Prestazione:
-17.47%
1 anno Prestazione:
-8.51%
Intervallo 1D:
$7.46
$8.40
Intervallo di 1 settimana:
$5.5148
$8.439
Portata 52W:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.17 | 451.41M | 0 | -119.87M | -109.90M | -1.81 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Research Analysts Set Expectations for ORIC FY2025 Earnings - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down – Here’s What Happened - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
ORIC-944 shows promise in combination with AR inhibitors in mCRPC - Urology Times
Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
Deutsche Bank AG Has $464,000 Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Outperform” Rating at Wedbush - Defense World
Traders Buy Large Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC) - Defense World
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - Asianet Newsable
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials - MSN
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study - sharewise
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
ORIC Pharmaceuticals shares surge on promising trial data By Investing.com - Investing.com South Africa
ORIC Pharmaceuticals shares surge on promising trial data - Investing.com Australia
ORIC Pharma jumps on promising data from prostate cancer drug trial - TradingView
Oric Pharmaceuticals (ORIC) Shows Promising Results in Cancer Drug Trial | ORIC Stock News - GuruFocus
ORIC Pharma's Prostate Cancer Drug Shows Encouraging Early Results; Upcoming Milestones Ahead - RTTNews
ORIC Pharmaceuticals (ORIC) Secures $125M in Private Stock Sale - GuruFocus
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
Oric Pharmaceuticals (ORIC) Secures $125M in Private Placement | - GuruFocus
ORIC Pharmaceuticals (ORIC) Secures $125M to Advance R&D - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement - Investing.com India
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Dat - GuruFocus
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Data for Prostate Cancer Treatment | ORIC Stock News - GuruFocus
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Prelim - GuruFocus
ORIC® Pharmaceuticals Announces $125 Million Private Placement F - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement By Investing.com - Investing.com Nigeria
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - The Manila Times
ORIC Lands Massive $125M Investment Led by SR One, Extending Runway Through Critical Phase 3 Cancer Trial - Stock Titan
ORIC Pharmaceuticals Showcases Cancer Drug Pipeline at Jefferies and Goldman Healthcare Conferences - Stock Titan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals: Promising Growth Potential with Superior Safety Profile and Strong Financial Position - TipRanks
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b - GlobeNewswire
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - The Manila Times
New Clinical Data: ORIC-944 Combination Therapy Shows Early Results for Advanced Prostate Cancer - Stock Titan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Acquires New Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts - MarketBeat
Sphera Funds Management LTD. Purchases 144,817 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Average Price Target from Analysts - Defense World
NEA Management Company LLC Buys 66,081 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Dimensional Fund Advisors LP Has $5.79 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Balyasny Asset Management L.P. Buys 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
(ORIC) Technical Data - news.stocktradersdaily.com
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
115,615 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):